Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) EBIT (2022 - 2025)

Historic EBIT for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • 60 Degrees Pharmaceuticals' EBIT fell 976.23% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.9 million, marking a year-over-year increase of 1716.02%. This contributed to the annual value of -$9.7 million for FY2024, which is 8847.17% down from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported EBIT of -$2.3 million as of Q3 2025, which was down 976.23% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' EBIT ranged from a high of -$215116.0 in Q3 2022 and a low of -$4.2 million during Q2 2024
  • In the last 4 years, 60 Degrees Pharmaceuticals' EBIT had a median value of -$1.6 million in 2023 and averaged -$1.6 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 60741.46% in 2023, then surged by 6168.72% in 2025.
  • 60 Degrees Pharmaceuticals' EBIT (Quarter) stood at -$684698.0 in 2022, then tumbled by 176.64% to -$1.9 million in 2023, then dropped by 9.02% to -$2.1 million in 2024, then fell by 12.61% to -$2.3 million in 2025.
  • Its EBIT was -$2.3 million in Q3 2025, compared to -$1.6 million in Q2 2025 and -$1.9 million in Q1 2025.